Medical Equipment Manufacturing · License Intelligence
Your R&D tools cost
millions. Do you know who is actually using them?
ANSYS, Siemens NX, MATLAB, and Altair licenses run $50,000–$1.8M per suite. Most medical device manufacturers manage them with spreadsheets — and carry a 21–30% buffer they never measure, justified only by the fear of an engineer waiting for a seat during an FDA submission sprint.
21%
Avg. license overspend in MedTech R&D orgs
$180K
Cost of 10% underutilization on a single ANSYS suite
529
FDA warning letters issued in 2024 — 8% to device makers
📄 Free Industry Brochure
License Intelligence for Medical Equipment Manufacturers
Get the full breakdown: ROI benchmarks, compliance mapping, and platform detail built specifically for MedTech R&D operations.
What you’ll get: ANSYS / Siemens NX / MATLAB utilization benchmarks, ISO 13485 audit trail mapping, Before/After comparison for MedTech R&D ops, and full platform capability detail.
See our partners in growth, trusted by leading innovators
Medical Equipment Manufacturing · License Intelligence
Engineering software is your
most expensive, least visible asset
Medical device development runs on simulation, CAD, and PLM tools that cost
more per seat than most SaaS stacks combined. Yet when your IT team is asked how many ANSYS tokens were
idle last quarter, the answer is almost always: we don’t know.
21–30%
License buffer overspend
The buffer tax every MedTech org quietly pays
Device manufacturers routinely over-provision simulation and CAD licenses to prevent any engineer from hitting a denial during a critical FDA submission window. That buffer — 21 to 30% on average — sits idle most of the time, billed at full enterprise rates.
$1.8M
Max cost per simulation suite
A single ANSYS Enterprise seat structure costs more than a clinical trial team
At $1.8M for a high-fidelity FEA/CFD suite, 10% underutilization represents $180,000 in pure waste — every year. Multiply that across your MATLAB, Siemens NX, and Altair portfolio, and the number becomes a budget conversation no one wants to have without data.
14.4%
CAGR — MedTech design services market
In-silico trials are replacing physical prototyping — license demand is growing fast
As FDA increasingly accepts simulation-based evidence for device submissions, software dependency is accelerating. Organizations shifting to in-silico clinical trials are adding tool complexity faster than their procurement and compliance teams can track it.
Operational Reality Check
The problems that surface atthe
worst possible moment
and they all share the same root cause: no real-time intelligence on engineering software usage.
R&D Velocity
R&D Velocity Engineers queued for ANSYS or Siemens NX seats during crunch time
License denials don’t send a calendar invite. They happen during a CFD simulation run at 11pm, or the morning before a design review when three engineers need the same Siemens NX module simultaneously.
⚑ Consequence: FDA submission timeline delayed. Every day of R&D delay in device development costs an estimated $30,000–$50,000 in extended team costs.
Compliance & Audit
Months of manual work to reconstruct "who used what" for a vendor audit
When Dassault, PTC, or Siemens audit your license compliance, you need an accurate, timestamped record of every checkout. If your team maintains this in Excel or via FLEXlm logs alone, reconciliation takes weeks — and the data is incomplete.
⚑ Consequence: True-up penalties, audit findings, and legal exposure. PTC true-up penalties have historically run 2–3× the annual license cost for gaps discovered in audit.
Regulatory
No audit trail for ISO 13485 Design History File requirements
ISO 13485 and FDA 21 CFR Part 820 require documented records of software used in device design. If your engineering tools don’t generate immutable, timestamped usage logs tied to specific design iterations, you have a compliance gap — whether or not it’s been surfaced in an inspection yet.
⚑ Consequence: FDA CDRH issued warning letters to 44 device manufacturers in 2024 for design validation and data integrity failures. Software traceability is part of that picture.
Financial Control
Renewal negotiations happen with no utilization data
When your ANSYS or MATLAB enterprise agreement comes up for renewal, your vendor sales team arrives with full telemetry on usage patterns. Your procurement team usually arrives with a guess. Without actual concurrent peak data, you’re negotiating from a position of zero leverage.
⚑ Consequence: Over-purchasing on renewal, or under-purchasing and triggering denials during the next crunch. Both outcomes cost more than the data would have.
Real-Time License Intelligence
Actual usage vs. idle time — broken down to the session
Standard ITAM tools tell you a program is “installed.” OpenLM tells you that your ANSYS Mechanical seat was checked out for 9.2 hours yesterday — but active for only 2.6 of them, with 6.6 hours billed while the engineer was at lunch.
Session-level granularity across every engineering tool
Tracks checkout time, active usage time, and idle periods for every license — per user, per workstation, per project. Not just “is it running” but “is anyone actually using it.”
Automated harvesting of idle licenses
Configurable inactivity thresholds automatically release licenses back to the pool when a workstation goes idle — without disrupting active work. The $50,000-seat-left-open-at-lunch problem, solved at the platform level.
Per-engineer, per-department, per-project breakdown
Usage data is attributable by user, team, and project. This is the input your ERP and SAM tools need for accurate R&D cost allocation — and what ISO 13485 DHF documentation requires for software traceability.
Regulatory Governance
Audit-ready in seconds, not months
ISO 13485
Design History File: Software traceability per clause 4.2.3 and 7.3
Every tool used during device design must be identifiable and traceable. OpenLM's session logs tie software usage directly to users, timestamps, and project context — meeting the DHF documentation requirement without manual reconstruction.
21 CFR 820
FDA Design Controls: Validated software records under 820.30(g)
FDA requires that any software used in the production or quality system of a device generates validated, retrievable records. Timestamped audit logs from OpenLM satisfy this requirement and can be exported for inspection readiness in seconds.
Vendor Audit
Dassault, PTC, Siemens: License compliance evidence on demand
Commercial software audits require proof of concurrent usage against entitlement. OpenLM maintains a continuous, accurate record of peak concurrent usage per product and feature — removing the weeks of manual log reconciliation your team currently faces.
Financial Intelligence
Right-size your license portfolio with data, not instinct
When your ANSYS or MATLAB enterprise agreement renews, OpenLM gives your procurement team the same usage telemetry your vendor already has — concurrent peak data, feature-level consumption, and project-level attribution. You stop guessing. You start negotiating.
Entitlement vs. demand gap analysis — feature by feature
OpenLM maps what you’re paying for against what your teams actually consumed at peak concurrent demand. The gap — visualized by tool, by feature module, by department — is your negotiating position at the next renewal table.
Chargeback telemetry for ERP and SAP integration
Project-level usage data feeds directly into your ERP and SAM systems for precise R&D cost allocation. Finance gets accurate departmental software spend. Project managers get verifiable software cost per device program.
True-up risk elimination before the audit letter arrives
True-up penalties from PTC, Dassault, or Siemens can run 2–3× your annual license cost when gaps are discovered in audit. Continuous monitoring ensures your entitlement always reflects actual peak usage — no surprises.
License Denial Analytics
License denials don't just frustrate engineers — they delay FDA submissions
Every time an engineer is denied a seat of ANSYS or Siemens NX, that event is logged, timestamped, and attributed. OpenLM surfaces denial patterns before they become a timeline problem — not after.
Identify which tools, which teams, and which time windows generate the most denials
Peak demand windows — typically pre-submission design freezes — are predictable once you have 90 days of denial data. OpenLM maps denial frequency by server, by workstation, and by time of day, giving operations the data to add capacity before the next crunch hits.
Quantify the R&D delay cost of each denial event
A single ANSYS denial during an FEA simulation run can delay a design iteration by hours — or push a submission milestone. OpenLM's denial duration tracking makes this cost visible, giving IT leadership a business case to right-size the portfolio ahead of renewal.
Zero-denial workflow through automated harvesting and proactive alerting
Configure idle thresholds per tool type. When a high-cost seat goes idle beyond the threshold, it's automatically returned to the pool — before the next denial occurs. Real-time alerts notify administrators when available seats drop below a configurable minimum.
Native MedTech Stack Integration
Built for the tools medical device engineers actually use
OpenLM provides deep, feature-level monitoring — not just process detection — for the engineering tools that drive MedTech R&D. Support extends across 90+ license managers, including FLEXlm, DSLS, and RMS, covering every major tool in the medical device design stack.
GDPR & HIPAA compliant data handling.
All usage telemetry is collected and stored in compliance with GDPR and HIPAA requirements — protecting researcher identity and project confidentiality. No simulation content is ever accessed or transmitted; only metadata (who, when, duration) is recorded.
Operational Outcomes
What changes for each team in your organization
License intelligence isn’t a single department problem. The downstream effects touch every function that touches R&D — from IT operations to regulatory affairs to finance.
| Team | Without OpenLM | With OpenLM |
|---|---|---|
| IT / SAM Operations | Manual FLEXlm log exports. Reactive — only knows about denials after engineers complain. Renewal decisions based on “what we bought last year.” | Real-time visibility across all license servers. Proactive alerts before denials occur. Renewal negotiations backed by 12 months of peak concurrent usage data. Continuous visibility |
| R&D Engineering | Engineers wait for seats during submission sprints. Workarounds (sharing credentials, using wrong tool versions) introduce compliance risk. Denials logged nowhere useful. | Automated harvesting of idle seats eliminates most denials. Zero-wait workflow during FDA submission windows. Usage patterns feed headcount and tooling planning. Zero-denial workflow |
| Regulatory Affairs | Reconstructing “what software was used in the design of this device” for a DHF takes weeks of manual investigation. ISO 13485 traceability is a recurring audit finding. | Immutable, timestamped records of every tool checkout — exportable per project, per design phase. ISO 13485 and 21 CFR 820 traceability requirements satisfied without manual effort. Audit-ready in seconds |
| Finance / Procurement | Enterprise agreements renewed based on headcount estimates. True-up exposure discovered only when the vendor audits. No per-project R&D software cost visibility. | Data-driven right-sizing eliminates buffer overspend. Per-project chargeback attribution feeds ERP. Procurement negotiates from peak concurrent usage facts, not guesses. Capital efficiency |
| Executive / CTO | R&D software is a black box cost. No KPI exists to track utilization efficiency. Compliance risk from software traceability gaps is invisible until inspection. | License utilization rate becomes a tracked operational KPI. Compliance gaps are surfaced proactively. CFO can see ROI on software spend for the first time. Measurable ROI |
Trusted across engineering-intensive industries
Your next vendor audit or FDA inspection window is already on the calendar
Download the OpenLM MedTech industry brochure — compliance mapping, ROI benchmarks, Before/After operational detail, and full platform capability for your R&D engineering stack.
